Table 1. Open in new tab Baseline...

Variables	Study Subjects (n = 624, 100%)
Age, y	60.9 ± 13.7	61.2 ± 14.8	60.6 ± 13.6	60.8 ± 12.1
Male sex	380 (60.9)	121 (47.1)	123 (67.9)^a	136 (73.1)^a
Weight, kg	58.7 ± 11.0	58.9 ± 10.9	58.6 ± 11.0	58.5 ± 11.1
BMI, kg/m²	22.2 ± 3.7	22.7 ± 3.7	21.9 ± 3.2	21.7 ± 3.9^a
LBM, kg	43.9 ± 8.8	42.5 ± 8.7	44.6 ± 8.9^a	45.2 ± 8.4^a
BFM, %	28.7 ± 7.8	30.8 ± 8.2	27.5 ± 6.7^a	26.7 ± 7.3^a
REE, kcal/d	1238 ± 210	1207 ± 214	1252 ± 213	1267 ± 198^a
REE/LBM, kcal/kg·d	27.1 ± 1.5	27.1 ± 1.6	27.0 ± 1.5	27.1 ± 1.4
Cancer stage IV	399 (63.9)	115 (44.7)	129 (71.3)^a	155 (83.3)^a,^b
ECOG PS 0–2	341 (54.7)	181 (70.4)	99 (54.7)	61 (32.8)
Time since diagnosis, d	209 [28–638]	179 [25–676]	241 [32–669]	216 [39–582]
Comorbidities
CHF	29 (4.7)	17 (6.6)	5 (2.7)	7 (3.7)
COPD	24 (3.9)	5 (1.9)	5 (2.7)	14 (7.5)^a,^b
Diabetes mellitus	163 (26.1)	73 (28.4)	55 (30.4)	35 (18.8)^a,^b
Liver cirrhosis	49 (7.8)	17 (6.6)	19 (10.5)	13 (6.9)
PTHrP, pmol/L	5.7 [2.8–10.1]	–	2.8 [1.6–4.2]	10.1 [6.8–14.4]^b
Corrected calcium, mg/dL	10.4 ± 1.8	9.7 ± 1.4	10.6 ± 1.6^a	11.3 ± 2.0^a,^b
Phosphate, mg/dL	3.3 ± 1.5	3.6 ± 1.2	3.3 ± 1.6	2.9 ± 1.6^a
Albumin, g/dL	3.1 ± 0.7	3.4 ± 0.8	3.0 ± 0.7^a	2.7 ± 0.5^a,^b
Hemoglobin, g/dL	10.3 ± 1.9	10.4 ± 2.0	10.2 ± 1.9	10.0 ± 1.7
Creatinine, mg/dL	1.3 ± 1.4	1.4 ± 1.7	1.2 ± 1.2	1.2 ± 1.0
eGFR, mL/min per 1.73 m²	77.8 ± 34.6	75.9 ± 36.7	78.7 ± 34.2	79.5 ± 32.1
CRP, mg/L	62.8 ± 74.7	42.9 ± 69.5	63.5 ± 73.8^a	87.6 ± 74.8^a,^b

Variables

Study Subjects (n = 624, 100%)

Total

PTHrP Not Detected (n = 257, 41.2%)

PTHrP < Median (n = 181, 29.0%)

PTHrP ≥ Median (n = 186, 29.8%)

Age, y

60.9 ± 13.7

61.2 ± 14.8

60.6 ± 13.6

60.8 ± 12.1

Male sex

380 (60.9)

121 (47.1)

123 (67.9)^a

136 (73.1)^a

Weight, kg

58.7 ± 11.0

58.9 ± 10.9

58.6 ± 11.0

58.5 ± 11.1

BMI, kg/m²

22.2 ± 3.7

22.7 ± 3.7

21.9 ± 3.2

21.7 ± 3.9^a

LBM, kg

43.9 ± 8.8

42.5 ± 8.7

44.6 ± 8.9^a

45.2 ± 8.4^a

BFM, %

28.7 ± 7.8

30.8 ± 8.2

27.5 ± 6.7^a

26.7 ± 7.3^a

REE, kcal/d

1238 ± 210

1207 ± 214

1252 ± 213

1267 ± 198^a

REE/LBM, kcal/kg·d

27.1 ± 1.5

27.1 ± 1.6

27.0 ± 1.5

27.1 ± 1.4

Cancer stage IV

399 (63.9)

115 (44.7)

129 (71.3)^a

155 (83.3)^a,^b

ECOG PS 0–2

341 (54.7)

181 (70.4)

99 (54.7)

61 (32.8)

Time since diagnosis, d

209 [28–638]

179 [25–676]

241 [32–669]

216 [39–582]

Comorbidities

CHF

29 (4.7)

17 (6.6)

5 (2.7)

7 (3.7)

COPD

24 (3.9)

5 (1.9)

5 (2.7)

14 (7.5)^a,^b

Diabetes mellitus

163 (26.1)

73 (28.4)

55 (30.4)

35 (18.8)^a,^b

Liver cirrhosis

49 (7.8)

17 (6.6)

19 (10.5)

13 (6.9)

PTHrP, pmol/L

5.7 [2.8–10.1]

–

2.8 [1.6–4.2]

10.1 [6.8–14.4]^b

Corrected calcium, mg/dL

10.4 ± 1.8

9.7 ± 1.4

10.6 ± 1.6^a

11.3 ± 2.0^a,^b

Phosphate, mg/dL

3.3 ± 1.5

3.6 ± 1.2

3.3 ± 1.6

2.9 ± 1.6^a

Albumin, g/dL

3.1 ± 0.7

3.4 ± 0.8

3.0 ± 0.7^a

2.7 ± 0.5^a,^b

Hemoglobin, g/dL

10.3 ± 1.9

10.4 ± 2.0

10.2 ± 1.9

10.0 ± 1.7

Creatinine, mg/dL

1.3 ± 1.4

1.4 ± 1.7

1.2 ± 1.2

1.2 ± 1.0

eGFR, mL/min per 1.73 m²

77.8 ± 34.6

75.9 ± 36.7

78.7 ± 34.2

79.5 ± 32.1

CRP, mg/L

62.8 ± 74.7

42.9 ± 69.5

63.5 ± 73.8^a

87.6 ± 74.8^a,^b

Variables	Study Subjects (n = 624, 100%)
Age, y	60.9 ± 13.7	61.2 ± 14.8	60.6 ± 13.6	60.8 ± 12.1
Male sex	380 (60.9)	121 (47.1)	123 (67.9)^a	136 (73.1)^a
Weight, kg	58.7 ± 11.0	58.9 ± 10.9	58.6 ± 11.0	58.5 ± 11.1
BMI, kg/m²	22.2 ± 3.7	22.7 ± 3.7	21.9 ± 3.2	21.7 ± 3.9^a
LBM, kg	43.9 ± 8.8	42.5 ± 8.7	44.6 ± 8.9^a	45.2 ± 8.4^a
BFM, %	28.7 ± 7.8	30.8 ± 8.2	27.5 ± 6.7^a	26.7 ± 7.3^a
REE, kcal/d	1238 ± 210	1207 ± 214	1252 ± 213	1267 ± 198^a
REE/LBM, kcal/kg·d	27.1 ± 1.5	27.1 ± 1.6	27.0 ± 1.5	27.1 ± 1.4
Cancer stage IV	399 (63.9)	115 (44.7)	129 (71.3)^a	155 (83.3)^a,^b
ECOG PS 0–2	341 (54.7)	181 (70.4)	99 (54.7)	61 (32.8)
Time since diagnosis, d	209 [28–638]	179 [25–676]	241 [32–669]	216 [39–582]
Comorbidities
CHF	29 (4.7)	17 (6.6)	5 (2.7)	7 (3.7)
COPD	24 (3.9)	5 (1.9)	5 (2.7)	14 (7.5)^a,^b
Diabetes mellitus	163 (26.1)	73 (28.4)	55 (30.4)	35 (18.8)^a,^b
Liver cirrhosis	49 (7.8)	17 (6.6)	19 (10.5)	13 (6.9)
PTHrP, pmol/L	5.7 [2.8–10.1]	–	2.8 [1.6–4.2]	10.1 [6.8–14.4]^b
Corrected calcium, mg/dL	10.4 ± 1.8	9.7 ± 1.4	10.6 ± 1.6^a	11.3 ± 2.0^a,^b
Phosphate, mg/dL	3.3 ± 1.5	3.6 ± 1.2	3.3 ± 1.6	2.9 ± 1.6^a
Albumin, g/dL	3.1 ± 0.7	3.4 ± 0.8	3.0 ± 0.7^a	2.7 ± 0.5^a,^b
Hemoglobin, g/dL	10.3 ± 1.9	10.4 ± 2.0	10.2 ± 1.9	10.0 ± 1.7
Creatinine, mg/dL	1.3 ± 1.4	1.4 ± 1.7	1.2 ± 1.2	1.2 ± 1.0
eGFR, mL/min per 1.73 m²	77.8 ± 34.6	75.9 ± 36.7	78.7 ± 34.2	79.5 ± 32.1
CRP, mg/L	62.8 ± 74.7	42.9 ± 69.5	63.5 ± 73.8^a	87.6 ± 74.8^a,^b

Table 1.

Open in new tab

Baseline Characteristics of Study Subjects by Serum PTHrP Levels

Variables	Study Subjects (n = 624, 100%)
Variables	Total	PTHrP Not Detected (n = 257, 41.2%)	PTHrP < Median (n = 181, 29.0%)	PTHrP ≥ Median (n = 186, 29.8%)
Age, y	60.9 ± 13.7	61.2 ± 14.8	60.6 ± 13.6	60.8 ± 12.1
Male sex	380 (60.9)	121 (47.1)	123 (67.9)^a	136 (73.1)^a
Weight, kg	58.7 ± 11.0	58.9 ± 10.9	58.6 ± 11.0	58.5 ± 11.1
BMI, kg/m²	22.2 ± 3.7	22.7 ± 3.7	21.9 ± 3.2	21.7 ± 3.9^a
LBM, kg	43.9 ± 8.8	42.5 ± 8.7	44.6 ± 8.9^a	45.2 ± 8.4^a
BFM, %	28.7 ± 7.8	30.8 ± 8.2	27.5 ± 6.7^a	26.7 ± 7.3^a
REE, kcal/d	1238 ± 210	1207 ± 214	1252 ± 213	1267 ± 198^a
REE/LBM, kcal/kg·d	27.1 ± 1.5	27.1 ± 1.6	27.0 ± 1.5	27.1 ± 1.4
Cancer stage IV	399 (63.9)	115 (44.7)	129 (71.3)^a	155 (83.3)^a,^b
ECOG PS 0–2	341 (54.7)	181 (70.4)	99 (54.7)	61 (32.8)
Time since diagnosis, d	209 [28–638]	179 [25–676]	241 [32–669]	216 [39–582]
Comorbidities
CHF	29 (4.7)	17 (6.6)	5 (2.7)	7 (3.7)
COPD	24 (3.9)	5 (1.9)	5 (2.7)	14 (7.5)^a,^b
Diabetes mellitus	163 (26.1)	73 (28.4)	55 (30.4)	35 (18.8)^a,^b
Liver cirrhosis	49 (7.8)	17 (6.6)	19 (10.5)	13 (6.9)
PTHrP, pmol/L	5.7 [2.8–10.1]	–	2.8 [1.6–4.2]	10.1 [6.8–14.4]^b
Corrected calcium, mg/dL	10.4 ± 1.8	9.7 ± 1.4	10.6 ± 1.6^a	11.3 ± 2.0^a,^b
Phosphate, mg/dL	3.3 ± 1.5	3.6 ± 1.2	3.3 ± 1.6	2.9 ± 1.6^a
Albumin, g/dL	3.1 ± 0.7	3.4 ± 0.8	3.0 ± 0.7^a	2.7 ± 0.5^a,^b
Hemoglobin, g/dL	10.3 ± 1.9	10.4 ± 2.0	10.2 ± 1.9	10.0 ± 1.7
Creatinine, mg/dL	1.3 ± 1.4	1.4 ± 1.7	1.2 ± 1.2	1.2 ± 1.0
eGFR, mL/min per 1.73 m²	77.8 ± 34.6	75.9 ± 36.7	78.7 ± 34.2	79.5 ± 32.1
CRP, mg/L	62.8 ± 74.7	42.9 ± 69.5	63.5 ± 73.8^a	87.6 ± 74.8^a,^b

Variables	Study Subjects (n = 624, 100%)
Variables	Total	PTHrP Not Detected (n = 257, 41.2%)	PTHrP < Median (n = 181, 29.0%)	PTHrP ≥ Median (n = 186, 29.8%)
Age, y	60.9 ± 13.7	61.2 ± 14.8	60.6 ± 13.6	60.8 ± 12.1
Male sex	380 (60.9)	121 (47.1)	123 (67.9)^a	136 (73.1)^a
Weight, kg	58.7 ± 11.0	58.9 ± 10.9	58.6 ± 11.0	58.5 ± 11.1
BMI, kg/m²	22.2 ± 3.7	22.7 ± 3.7	21.9 ± 3.2	21.7 ± 3.9^a
LBM, kg	43.9 ± 8.8	42.5 ± 8.7	44.6 ± 8.9^a	45.2 ± 8.4^a
BFM, %	28.7 ± 7.8	30.8 ± 8.2	27.5 ± 6.7^a	26.7 ± 7.3^a
REE, kcal/d	1238 ± 210	1207 ± 214	1252 ± 213	1267 ± 198^a
REE/LBM, kcal/kg·d	27.1 ± 1.5	27.1 ± 1.6	27.0 ± 1.5	27.1 ± 1.4
Cancer stage IV	399 (63.9)	115 (44.7)	129 (71.3)^a	155 (83.3)^a,^b
ECOG PS 0–2	341 (54.7)	181 (70.4)	99 (54.7)	61 (32.8)
Time since diagnosis, d	209 [28–638]	179 [25–676]	241 [32–669]	216 [39–582]
Comorbidities
CHF	29 (4.7)	17 (6.6)	5 (2.7)	7 (3.7)
COPD	24 (3.9)	5 (1.9)	5 (2.7)	14 (7.5)^a,^b
Diabetes mellitus	163 (26.1)	73 (28.4)	55 (30.4)	35 (18.8)^a,^b
Liver cirrhosis	49 (7.8)	17 (6.6)	19 (10.5)	13 (6.9)
PTHrP, pmol/L	5.7 [2.8–10.1]	–	2.8 [1.6–4.2]	10.1 [6.8–14.4]^b
Corrected calcium, mg/dL	10.4 ± 1.8	9.7 ± 1.4	10.6 ± 1.6^a	11.3 ± 2.0^a,^b
Phosphate, mg/dL	3.3 ± 1.5	3.6 ± 1.2	3.3 ± 1.6	2.9 ± 1.6^a
Albumin, g/dL	3.1 ± 0.7	3.4 ± 0.8	3.0 ± 0.7^a	2.7 ± 0.5^a,^b
Hemoglobin, g/dL	10.3 ± 1.9	10.4 ± 2.0	10.2 ± 1.9	10.0 ± 1.7
Creatinine, mg/dL	1.3 ± 1.4	1.4 ± 1.7	1.2 ± 1.2	1.2 ± 1.0
eGFR, mL/min per 1.73 m²	77.8 ± 34.6	75.9 ± 36.7	78.7 ± 34.2	79.5 ± 32.1
CRP, mg/L	62.8 ± 74.7	42.9 ± 69.5	63.5 ± 73.8^a	87.6 ± 74.8^a,^b

Data are presented as either mean ± SD or n (percentage). PTHrP values were presented as median [interquartile ranges]. –, not available.

P < .05 compared with PTHrP negative group.

P < .05 compared with PTHrP < median group.

This Feature Is Available To Subscribers Only